VRCA

Verrica Pharmaceuticals Inc. Common Stock

4.62

USD

VRCA Earnings Reports

Positive Surprise Ratio

VRCA beat 17 of 31 last estimates.

55%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

$4.69M

-$0.47

Implied change from Q4 25 (Revenue/ EPS)

-7.86%

+2.17%

Implied change from Q1 25 (Revenue/ EPS)

+37.11%

-53.00%

Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue

On Mar 11, 2026, VRCA reported earnings of -0.46 USD per share (EPS) for Q4 25, beating the estimate of -0.81 USD, resulting in a 43.22% surprise. Revenue reached 5.09 million, compared to an expected 4.62 million, with a 10.32% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.47 USD, with revenue projected to reach 4.69 million USD, implying an increase of 2.17% EPS, and decrease of -7.86% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Relmada Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.14

Actual

-$0.28

Surprise

-103.08%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

FAQ

What were Verrica Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.46, beating estimates by 43.22%, and revenue of $5.09M, 10.32% above expectations.

How did the market react to Verrica Pharmaceuticals Inc. Common Stock's Q4 2025 earnings?

The stock price moved -- 0%, changed from $5.47 before the earnings release to $5.47 the day after.

When is Verrica Pharmaceuticals Inc. Common Stock expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Verrica Pharmaceuticals Inc. Common Stock's next earnings report?

Based on 4 analysts, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.47 and revenue of $4.69M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.